ASP Inhibitors

ASP inhibitors encompass a group of chemicals that can indirectly affect the activity of Aspartate Aminotransferase by interacting with its associated metabolic pathways. These chemicals can modify the enzyme's activity through various mechanisms, such as inhibiting cofactor interactions, competing with substrates, or altering the availability of crucial coenzymes. Inhibitors like Aminooxyacetic acid and Hydroxylamine target the enzyme's requirement for pyridoxal phosphate, binding to this coenzyme and rendering it unavailable for catalytic activity. Compounds such as Malonate and Phenylbutazone can affect AST by interfering with related metabolic pathways, leading to changes in substrate concentration or enzyme binding capacity. Drugs like Methotrexate and Azaserine, which interfere with nucleotide and amino acid synthesis, can have knock-on effects on the transamination reactions AST carries out. Some inhibitors operate by causing a deficiency in essential coenzymes or by inducing conditions that lead to enzyme dysfunction. Allyl formate causes pyridoxine deficiency, which has downstream effects on AST activity, while ethanol's impact on liver function can alter AST levels. Chloroquine and Valproic acid are associated with liver toxicity or dysfunction, which can be reflected in altered AST activity as part of a broader spectrum of hepatic enzyme disturbances.